Drug Profile
Trehalose - Junaxo
Alternative Names: JNX-3001Latest Information Update: 01 Jan 2022
Price :
$50
*
At a glance
- Originator Junaxo
- Class Antidementias; Disaccharides; Glucans; Pyrrolidines; Small molecules
- Mechanism of Action Protein aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in Canada (PO)